The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Baveno VII – Renewing consensus in portal hypertension
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.022 · Cited by 2,930
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Global Burden of 5 Major Types of Gastrointestinal Cancer
Arnold, M., Abnet, C. C., Neale, R. E., Vignat, J., Giovannucci, E. L., McGlynn, K. A., & Bray, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.068 · Cited by 2,027
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883 · cited 1×
“The rollout of universal HBV vaccination among newborns, first introduced in Taiwan nearly 40 years ago and gradually adopted in most parts of the region 101,102 , has successfully reduced childhood infections over the past three decades.”
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029349 · Cited by 1,146 · cited 1×
“More than half of the global population living with MASLD is in the Asia-Pacific region, but paradoxically, there has been an under-representation of this population in natural history studies 169 and drug trials 170 .”
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925
Self-citationGlobal alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study
Manthey, J., Shield, K. D., Rylett, M., Hasan, O. S. M., Probst, C., & Rehm, J. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32744-2 · Cited by 856
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Self-citation2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Self-citationGlobal burden of hepatitis B virus: current status, missed opportunities and a call for action
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00760-9 · Cited by 632 · cited 1×
“The Asia-Pacific region bears the greatest burden of HBV infection globally 21 .”
Self-citationIncidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615 · cited 3×
“…and alternative medicines (CAM) are associated with the risk of drug interactions and DILI, with reported incidence rates of 14 per 100,000 population in France 67 (for example, as a Western country), 12 per 100,000 population in South Korea 68 and 24 per 100,000 population in China 69 .”
International trends in hepatocellular carcinoma incidence, 1978–2012
Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., Ferlay, J., Valery, P. C., Bray, F., & McGlynn, K. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32723 · Cited by 594 · cited 1×
“in many countries in the region between the 1970s and 1990s, with average annual percentage changes ranging from −1.5% to −4.0% 129–131 .”
InfluentialRisks of chronicity following acute hepatitis B virus infection: a review.
Hyams, K. C. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.4.992 · Cited by 521
Pathogenesis of alcoholic liver disease: Role of oxidative metabolism
Ceni, E., Mello, T., & Galli, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17756 · Cited by 521
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Update on NAFLD genetics: From new variants to the clinic
Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393
Can we use old NAFLD data under the new MASLD definition?
Song, S. J., Lai, J. C.-T., Wong, G. L.-H., Wong, V. W.-S., & Yip, T. C.-F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.021 · Cited by 374
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D., & Singal, A. G. (2021) · Hepatology · doi:10.1002/hep.31309 · Cited by 333
Underestimation of liver‐related mortality in the United States
Asrani, S. K., Larson, J. J., Yawn, B., Therneau, T. M., & Kim, W. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.04.005 · Cited by 311
India: alcohol and public health
BENEGAL, V. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01176.x · Cited by 232
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327777 · Cited by 110 · cited 1×
“…advanced CLD (cACLD), that consists of a spectrum of advanced liver fibrosis and compensated cirrhosis diagnosed by transient elastography in combination with platelet count, includes patients with clinically significant portal hypertension (CSPH) who are at higher risk of decompensation 85,86 .”
Self-citationDrug-Induced Acute-on-Chronic Liver Failure in Asian Patients
Devarbhavi, H., Choudhury, A. K., Sharma, M. K., Maiwall, R., Al Mahtab, M., Rahman, S., Chawla, Y. K., Dhiman, R. K., Duseja, A., Taneja, S., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000201 · Cited by 85 · cited 3×
“The use of hepatotoxic antituberculous medications in the tuberculosis-endemic regions within the Asia-Pacific region and the unregulated use of CAM increases the prevalence of ACLF 19,118 .”
InfluentialSelf-citationChinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Acute-on-chronic liver failure: far to go—a review
Luo, J., Li, J., Li, P., Liang, X., Hassan, H. M., Moreau, R., & Li, J. (2023) · Critical Care · doi:10.1186/s13054-023-04540-4 · Cited by 54
Philips, C. A., Paramaguru, R., Augustine, P., Rajesh, S., Ahamed, R., George, T., & Padsalgi, G. (2019) · Hepatology Communications · doi:10.1002/hep4.1355 · Cited by 32 · cited 1×
“The estimates for the prevalence of CAM use are heterogeneous and vary substantially by location; a single-centre study in India found that 68% of patients with cirrhosis used CAM at some point 71 .”
Cited by
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N. D., Abou-Alfa, G. K., Singal, A. G., & Yang, J. D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 306
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Self-citationSun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T. (2025) · Liver Cancer · doi:10.1159/000548536 · Cited by 3
Self-citation
Metadata
- Authors
- Mak, L.-Y., Liu, K., Chirapongsathorn, S., Yew, K. C., Tamaki, N., Rajaram, R. B., Panlilio, M. T., Lui, R., Lee, H. W., Lai, J. C.-T., Kulkarni, A. V., Premkumar, M., Lesmana, C. R. A., Hsu, Y. C., & Huang, D. Q.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2024-08-15
- Volume
- 21
- Issue
- 12
- Pages
- 834-851
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W4401614855
- Cited by
- 182
- References
- 38
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.